modelOxyphenbutazone
Extends from Pharmacolibrary.Drugs.ATC.M.M02AA04.
Information
| name: | Oxyphenbutazone | |
| ATC code: | M02AA04 | route: | oral |
| compartments: | 1 | |
| dosage: | 150 | mg |
| volume of distribution: | 0.16 | L |
| clearance: | 0.025 | L/hr/kg |
| other parameters in model implementation | ||
Oxyphenbutazone is a nonsteroidal anti-inflammatory drug (NSAID) in the pyrazolidinedione class, formerly used for the treatment of pain and inflammation in conditions like arthritis. Due to significant safety concerns, including serious adverse hematologic reactions, it is no longer approved or widely used in most countries.
Pharmacokinetics
Estimated pharmacokinetic parameters for healthy adults based on available references for structurally similar NSAIDs and limited legacy reports. No published detailed compartmental PK models found for oxyphenbutazone.
References
Chay, S, et al., & Yocum, J (1984). Population distributions of phenylbutazone and oxyphenbutazone after oral and i.v. dosing in horses. Journal of veterinary pharmacology and therapeutics 7(4) 265–276. DOI:10.1111/j.1365-2885.1984.tb00911.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/6512917
Brouwers, JR, & de Smet, PA (1994). Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs. Clinical pharmacokinetics 27(6) 462–485. DOI:10.2165/00003088-199427060-00005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/7882636
Tobin, T, et al., & Lees, P (1986). Phenylbutazone in the horse: a review. Journal of veterinary pharmacology and therapeutics 9(1) 1–25. DOI:10.1111/j.1365-2885.1986.tb00008.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/3517382
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)